Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 2/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15563826 | 0.87 | ALDH1A1 (0.52) | SMN1; SMN2MAPTRAB9APPARDPPARA | |
| SCHEMBL6603045 | 0.84 | KDM4E (0.51) | SMN1; SMN2MAPTRAB9APPARDPPARA | |
| SCHEMBL15563505 | 0.84 | MAPT (0.50) | SMN1; SMN2MAPTRAB9AHSD17B10PPARD | |
| SCHEMBL15945345 | 0.84 | MAPT (0.55) | SMN1; SMN2MAPTRAB9AHSD17B10KDM4E | |
| SCHEMBL6608984 | 0.84 | HTT (0.58) | SMN1; SMN2MAPTHTT | |
| SCHEMBL11218527 | 0.83 | MAPT (0.47) | SMN1; SMN2MAPTRAB9AHSD17B10PPARD | |
| SCHEMBL3715949 | 0.83 | KDM4E (0.56) | SMN1; SMN2MAPTRAB9AHSD17B10PPARD | |
| SCHEMBL22263501 | 0.83 | PPARD (0.47) | SMN1; SMN2MAPTRAB9APPARDPPARA | |
| SCHEMBL31423348 | 0.83 | KDM4E (0.56) | SMN1; SMN2MAPTRAB9AHSD17B10PPARD | |
| SCHEMBL4432713 | 0.81 | IKBKB (0.61) | SMN1; SMN2MAPTRAB9APPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783501-B2 | Substituted quinolines as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-10-10 | — | — | US | disclosed |
| US-20150336945-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-11-26 | — | — | US | disclosed |
| US-9139529-B2 | Substituted quinoxalines as sodium channel modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140228371-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336945-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN5A, SCN1A, SCN2A | SMN1; SMN2 900/4885MAPT 2538/4885RAB9A 1156/4885 |
| US-20140228371-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN5A, SCN1A, SCN2A | SMN1; SMN2 900/4885MAPT 2538/4885RAB9A 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.